BACKGROUND: Severe acute respiratory syndrome (SARS) is an emerging viral infectious disease. We report our experience in treating SARS patients. METHODS: From April 27 to May 24, 2003, a total of 36 patients with probable SARS were admitted and treated in a hospital rearranged as a special center for the management of SARS patients. Medical records for the patients were retrospectively reviewed. Univariate and multivariate analyses were performed to determine factors associated with respiratory failure and intubation. RESULTS: Of the 36 patients with probable SARS (median age, 37 years; range, 22-66 years), 9 were male and 27 were female. Thirty-two patients (88.9%) were infected in the hospital setting. All patients presented with fever, and 33 eventually developed lymphopenia during hospitalization. Chest radiography showed no unique pattern, but pleural effusion was not seen. All patients initially received empiric antibacterial therapy against common causative pathogens of atypical pneumonia. Ribavirin was given to all except 1 patient. Twenty-two patients received immunoglobulin therapy, and 32 were given corticosteroids. A total of 20 patients (55.6%) required supplemental oxygen, and 8 (22.2%) were intubated with mechanical ventilatory support. Two of these patients died. A higher body temperature at presentation (median 39.5 vs 38.6 degrees C), and higher peak values of lactate dehydrogenase (410 vs 282 U/L) and C-reactive protein (10.2 vs 2.5 mg/dL), were associated with subsequent respiratory failure. Multivariate analysis showed that peak level of C-reactive protein was the only independent predictor of respiratory failure and intubation (odds ratio for every increment of 1 mg/dL = 1.45; 95% confidence interval = 1.003, 2.097; p = 0.048). CONCLUSION: All patients with probable SARS who were admitted to hospital presented with fever and lymphopenia. While the efficacy of different treatments could not be evaluated from this retrospective study, a higher value of C-reactive protein was associated with the development of respiratory failure and subsequent intubation.
BACKGROUND:Severe acute respiratory syndrome (SARS) is an emerging viral infectious disease. We report our experience in treating SARSpatients. METHODS: From April 27 to May 24, 2003, a total of 36 patients with probable SARS were admitted and treated in a hospital rearranged as a special center for the management of SARSpatients. Medical records for the patients were retrospectively reviewed. Univariate and multivariate analyses were performed to determine factors associated with respiratory failure and intubation. RESULTS: Of the 36 patients with probable SARS (median age, 37 years; range, 22-66 years), 9 were male and 27 were female. Thirty-two patients (88.9%) were infected in the hospital setting. All patients presented with fever, and 33 eventually developed lymphopenia during hospitalization. Chest radiography showed no unique pattern, but pleural effusion was not seen. All patients initially received empiric antibacterial therapy against common causative pathogens of atypical pneumonia. Ribavirin was given to all except 1 patient. Twenty-two patients received immunoglobulin therapy, and 32 were given corticosteroids. A total of 20 patients (55.6%) required supplemental oxygen, and 8 (22.2%) were intubated with mechanical ventilatory support. Two of these patients died. A higher body temperature at presentation (median 39.5 vs 38.6 degrees C), and higher peak values of lactate dehydrogenase (410 vs 282 U/L) and C-reactive protein (10.2 vs 2.5 mg/dL), were associated with subsequent respiratory failure. Multivariate analysis showed that peak level of C-reactive protein was the only independent predictor of respiratory failure and intubation (odds ratio for every increment of 1 mg/dL = 1.45; 95% confidence interval = 1.003, 2.097; p = 0.048). CONCLUSION: All patients with probable SARS who were admitted to hospital presented with fever and lymphopenia. While the efficacy of different treatments could not be evaluated from this retrospective study, a higher value of C-reactive protein was associated with the development of respiratory failure and subsequent intubation.
Authors: S Konoplev; R E Champlin; S Giralt; N T Ueno; I Khouri; I Raad; K Rolston; K Jacobson; J Tarrand; M Luna; Q Nguyen; E Whimbey Journal: Bone Marrow Transplant Date: 2001-04 Impact factor: 5.483
Authors: Suzana M A Lobo; Francisco R M Lobo; Daliana Peres Bota; Flavio Lopes-Ferreira; Hosam M Soliman; Christian Mélot; Jean-Louis Vincent Journal: Chest Date: 2003-06 Impact factor: 9.410
Authors: Christopher M Booth; Larissa M Matukas; George A Tomlinson; Anita R Rachlis; David B Rose; Hy A Dwosh; Sharon L Walmsley; Tony Mazzulli; Monica Avendano; Peter Derkach; Issa E Ephtimios; Ian Kitai; Barbara D Mederski; Steven B Shadowitz; Wayne L Gold; Laura A Hawryluck; Elizabeth Rea; Jordan S Chenkin; David W Cescon; Susan M Poutanen; Allan S Detsky Journal: JAMA Date: 2003-05-06 Impact factor: 56.272
Authors: Z Zhao; F Zhang; M Xu; K Huang; W Zhong; W Cai; Z Yin; S Huang; Z Deng; M Wei; J Xiong; P M Hawkey Journal: J Med Microbiol Date: 2003-08 Impact factor: 2.472
Authors: Raymond S M Wong; Alan Wu; K F To; Nelson Lee; Christopher W K Lam; C K Wong; Paul K S Chan; Margaret H L Ng; L M Yu; David S Hui; John S Tam; Gregory Cheng; Joseph J Y Sung Journal: BMJ Date: 2003-06-21
Authors: T Shirai; K Sano; S Matsuyama; Y Honjo; M Takashima; Y Sasada; S Takayanagi; K Nagamatsu; M Nawano; M Fushimi; S Imokawa; A Sato Journal: Intern Med Date: 1996-04 Impact factor: 1.271
Authors: Ga Eun Park; Cheol In Kang; Jae Hoon Ko; Sun Young Cho; Young Eun Ha; Yae Jean Kim; Kyong Ran Peck; Jae Hoon Song; Doo Ryeon Chung Journal: J Korean Med Sci Date: 2017-01 Impact factor: 2.153
Authors: Matthew P Muller; Linda Dresser; Janet Raboud; Allison McGeer; Elizabeth Rea; Susan E Richardson; Tony Mazzulli; Mark Loeb; Marie Louie Journal: Pharmacotherapy Date: 2007-04 Impact factor: 4.705
Authors: Ibrahim Y Hachim; Mahmood Y Hachim; Haifa Hannawi; Kashif Bin Naeem; Abdulla Salah; Suad Hannawi Journal: PLoS One Date: 2021-12-02 Impact factor: 3.240